Frost & Sullivan has awarded Cell Science Systems Corporation (CSS, Deerfield, FL) the 2016 North American Company of the Year Award, based on Frost & Sullivan’s recent analysis of the food intolerance testing market.
“CSS has conducted ongoing research for more than 20 years to perfect its flagship Alcat Test, a cellular test for foods, chemicals molds, functional foods, additives, and drugs,” said Frost & Sullivan Research Analyst Aishwarya Vivekanandan. “The company’s advanced testing solutions present valuable advice and quantitative data that aid customers in changing their food habits to lead healthier, happier lives.”
The CSS Alcat Test is the only technology in the market to have been clinically validated after rigorous tests by independent bodies as well as the only diagnostics company to be a U.S. Food and Drug Administration (FDA)-registered medical device manufacturer that voluntarily maintains ISO EN 13485 certification.
“We are delighted to be recognized as a leader in the food sensitivity and intolerance testing market,” said Roger Deutsch, president and CEO of CSS. “Recent clinical testing continues to indicate the importance of understanding the relationship between food sensitivities, inflammation and the innate immune system in our overall health and wellness.”
Each year, Frost & Sullivan presents this award to the company that has demonstrated superiority in devising a strong growth strategy and implementing it. The recipient must demonstrate strength in terms of innovation in products and technologies, leadership in customer value, as well as speed in response to market needs. In short, the award looks at the emerging market players in the industry and recognizes their best practices that position them for future growth.
CSS enables in-vitro testing that identifies changes in blood cell sizes. After the mechanical removal of red blood cells, white blood cells are incubated with purified food extracts or other test substances through the impedance method of particle sizing and counting. A proprietary algorithm facilitates statistical comparison of a patient’s normal cell profile with post-incubation samples.
“No single immune factor, antibody, or cytokine has been—or is likely to be—identified as the standard biomarker of food sensitivity. Therefore, the Alcat Test in-vitro method is unlikely to be supplanted by any existing or future assay,” said Vivekanandan. “As the awareness of a validated methodology for assessing patient-specific triggers of inflammation rises, many more mainstream health care providers will adopt the test.”
For more information, visit www.cellsciencesystems.com.